Previous 10 | Next 10 |
Theravance Biopharma press release ( NASDAQ: TBPH ): Q3 GAAP EPS of -$0.21 misses by $0.18 . Revenue of $12.5M (-5.3% Y/Y) misses by $3.46M . For further details see: Theravance Biopharma GAAP EPS of -$0.21 misses by $0.18, revenue of $12.5M misses by $3....
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Theravance Biopharma, Inc. 2022 Q3 - Results - Earnings Call Presentation
Theravance Biopharma, Inc. (TBPH) Q3 2022 Earnings Conference Call November 7, 2022 05:00 PM ET Company Participants Rick Winningham – Chairman and Chief Executive Officer Rhonda Farnum – Senior Vice President, Chief Business Officer Rick Graham ...
Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer PR Newswire Reported another record quarter of YUPELRI ® (revefenacin) net sales and profitability: $18.7 million Q3 2022 sales up ...
Theravance Biopharma ( NASDAQ: TBPH ) is scheduled to announce Q3 earnings results on Monday, November 7th, after market close. The consensus EPS Estimate is -$0.04 and the consensus Revenue Estimate is $11.81M (-10.5% Y/Y). Over the last 3 months, EPS estimates have s...
Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System PR Newswire Totality of Evidence from the Phase 3 Clinical Program Demonstrates Ampreloxetine was Effective in Treating Sympto...
Theravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022 PR Newswire DUBLIN , Oct. 31, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2022 financial results and provide a bu...
Theravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous System PR Newswire DUBLIN , Oct. 25, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravanc...
Theravance Biopharma, Inc. ( NASDAQ: TBPH ), a company focused on respiratory disorders, announced Wednesday a tender offer to purchase $95M of its ordinary shares at a price range of $9.75 – $10.50 per share. The "modified Dutch auction" tender offer is expected to...
Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares PR Newswire DUBLIN , Sept. 28, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced a "modified Du...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...